Format

Send to

Choose Destination
Curr Drug Targets. 2019 Mar 25. doi: 10.2174/1389450120666190325130142. [Epub ahead of print]

Vedolizumab in the perioperative management of inflammatory bowel disease.

Author information

1
Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, Minnesota. United States.
2
Division of Gastroenterology, Mayo Clinic, Rochester, Minnesota. United States.

Abstract

BACKGROUND:

The isolated effect of vedolizumab on increased postoperative complications remains debated, similar to the controversial data on anti-TNF and postoperative complications.

OBJECTIVE:

Determine the risk of vedolizumab on postoperative complications.

METHOD:

A review of the literature available to date on studies comparing postoperative outcomes in vedolizumab-treated versus non-vedolizumab-treated patients was performed. Studies were stratified by those which combined all inflammatory bowel disease together, those specifically focusing on Crohn's disease or ulcerative colitis individually, and those which included pediatric patients alone.

RESULTS:

The data remains controversial in both the adult and pediatric literature regarding the association of vedolizumab and increased postoperative complications. The strongest association between vedolizumab and an increased risk of postoperative infectious complications seems to be in the Crohn's disease literature.

CONCLUSION:

Vedolizumab may be associated with an increased risk of postoperative infectious complications in Crohn's disease, but the literature remains controversial due to difficulty in isolating the effect of the biologic alone in a chronically ill, heterogeneous patient population who are on multiple medications including corticosteroids.

KEYWORDS:

Crohn’s disease; inflammatory bowel disease; intra-abdominal sepsis; postoperative infectious complications; surgical intervention; ulcerative colitis ; vedolizumab

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center